Is CA 19-9 useful in the management of pancreatic cancer?

被引：16
作者：
Balzano, Gianpaolo [1 ]
Di Carlo, Valerio [1 ]
机构：
[1] Ist Sci San Raffaele, Dept Surg, Pancreas Unit, I-20132 Milan, Italy
来源：
LANCET ONCOLOGY | 2008年 / 9卷 / 02期
关键词：
D O I：
10.1016/S1470-2045(08)70011-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：89 / 91
页数：3
相关论文
共 8 条
[1]   Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study [J].
Berrino, Franco ;
De Angelis, Roberta ;
Sant, Milena ;
Rosso, Stefano ;
Lasota, Magdalena B. ;
Coebergh, Jan W. ;
Santaquilani, Mariano .
LANCET ONCOLOGY, 2007, 8 (09) :773-783
[2]   Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer [J].
Boeck, Stefan ;
Stieber, Petra ;
Holdenrieder, Stefan ;
Wilkowski, Ralf ;
Heinemann, Volker .
ONCOLOGY, 2006, 70 (04) :255-264
[3]   Recent major progress in long-term cancer patient survival disclosed by modeled period analysis [J].
Brenner, Hermann ;
Gondos, Adam ;
Arndt, Volker .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (22) :3274-3280
[4]   CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial [J].
Hess, Viviane ;
Glimelius, Bengt ;
Grawe, Philipp ;
Dietrich, Daniel ;
Bodoky, Gyoergy ;
Ruhstaller, Thomas ;
Bajetta, Emilio ;
Saletti, Piercarlo ;
Figer, Arie ;
Scheithauer, Werner ;
Herrmann, Richard .
LANCET ONCOLOGY, 2008, 9 (02) :132-138
[5]   Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancer [J].
Ko, AH ;
Hwang, J ;
Venook, AP ;
Abbruzzese, JL ;
Bergsland, EK ;
Tempero, MA .
BRITISH JOURNAL OF CANCER, 2005, 93 (02) :195-199
[6]   Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer:: Results of a GERCOR and GISCAD phase III trial [J].
Louvet, C ;
Labianca, R ;
Hammel, P ;
Lledo, G ;
Zampino, MG ;
André, T ;
Zaniboni, A ;
Ducreux, M ;
Aitini, E ;
Taïeb, J ;
Faroux, R ;
Lepere, C ;
de Gramont, A .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (15) :3509-3516
[7]   THE PROGNOSTIC VALUE OF PREOPERATIVE SERUM LEVELS OF CA-19-9 AND CEA IN PATIENTS WITH PANCREATIC-CANCER [J].
LUNDIN, J ;
ROBERTS, PJ ;
KUUSELA, P ;
HAGLUND, C .
BRITISH JOURNAL OF CANCER, 1994, 69 (03) :515-519
[8]   CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials [J].
Maisey, NR ;
Norman, AR ;
Hill, A ;
Massey, A ;
Oates, J ;
Cunningham, D .
BRITISH JOURNAL OF CANCER, 2005, 93 (07) :740-743
1